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Abstract 
Background:  Selenium is known to be important to the brain, retaining it even in 
deficiency. To date, three small, published studies have suggested an effect of selenium 
supplementation or deprivation on mood in healthy volunteers.  We investigated these 
findings on a much larger scale. 
 
Methods: In this double-blind, placebo-controlled, multi-centre intervention trial, 501 UK 
subjects aged 60-74 were randomly allocated to receive 100, 200 or 300µg selenium per day 
as high-selenium yeast or placebo yeast.  Main outcome measures were: mood (POMS-BI 
questionnaire), "quality of life" (SF-36 questionnaire) and plasma selenium (ICP-MS).  Each 
was measured at baseline and six months as planned in the protocol.  
 
Results: Supplementation significantly increased plasma selenium concentrations above 
baseline values: from an overall mean (SD) of 90 (19) ng/g to 91 (26), 144 (27), 191 (41) and 
227 (53) ng/g in the placebo, 100, 200, 300µg selenium groups respectively (p < 0.001).  448 
participants completed the POMS-BI questionnaires at both time points, with no significant 
differences in total mood or mood-subscale scores seen between the treatment doses.  After 
six months of supplementation, mean (SD) total mood scores for the four tablet doses were 
163 (36), 161 (37), 162 (33), 162 (34), F3,443 = 0.25, p = 0.86.  Quality of life was similarly 
unaffected by supplementation. 
 
Conclusions: Selenium supplementation did not appear to benefit mood or quality of life in 
these elderly volunteers.  Though this is at odds with some previous results, our robust study 
design, much larger sample size and longer supplementation period, together with the 
evidence that the brain is a privileged site for selenium retention, suggest that this is a reliable 
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finding. We therefore find no justification for increasing selenium intake with the aim of 
improving mood in this population. 
 
 
Key words: selenium, mood, quality of life, elderly, POMS-BI, SF-36 
 
Margaret Rayman: m.rayman@surrey.ac.uk 4
 The assertion that selenium enhances mood is now commonly encountered both in the 
scientific (Rayman 2000) and in the popular press, yet is based on the results of only a few, 
small studies.  We therefore took the opportunity to test this interesting hypothesis while 
conducting a pilot study for a much larger randomized trial that supplemented participants 
with selenium. 
There are a number of indications that selenium is important to the brain: during 
selenium depletion the brain receives a priority supply (Behne et al 1988; Buckman et al 
1993; Whanger 2001); neurotransmitter turnover rate is altered in selenium deficiency 
(Castano et al 1997); selenium supplementation can reduce intractable epileptic seizures 
(Weber et al 1991, Ramaekers 1994); low plasma selenium levels in the elderly have been 
associated with senility and accelerated cognitive decline (Berr et al 2000); Alzheimer’s 
patients have lower brain selenium concentrations than controls (Corrigan et al 1991); sodium 
selenite protected against dopamine loss in a rat model of Parkinson’s disease (Zafar et al 
2003); a selenoenzyme (GPx1) protected against neuron loss in a mouse stroke model (Crack 
et al 2001).  Furthermore, as the brain is deficient in catalase (Halliwell and Gutteridge 1985), 
peroxidation products such as H2O2 and lipid peroxides must be removed by the antioxidant 
selenoenzymes.  
With respect to mood, two published studies have shown a beneficial effect of 
selenium as measured by the Profile of Moods States - Bipolar Form (POMS-BI) 
questionnaire (Lorr and McNair 1984).  In a US study where 30 selenium-replete men were 
fed either a low (32.6µg/d) or high (226.5µg/d) selenium diet for 15 weeks, the mood of 
those on the low selenium diet significantly worsened while that of those on the high 
selenium diet significantly improved (Finley and Penland 1998).   Unfortunately it is not clear 
whether diet type was allocated randomly.  A similar finding was obtained in a double-blind 
crossover study of 50 UK subjects (Benton and Cook 1991).  Here, a daily 100µg selenium 
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supplement as high-selenium yeast significantly decreased anxiety, depression and tiredness, 
with the effect being most marked in subjects consuming lesser amounts of dietary selenium 
(estimated by a food-frequency questionnaire).  However, a further US study involving 11 
men of adequate selenium status randomized to high (356 µg/d) or low (13 µg/d) selenium 
diets for 99 days failed to show any change in mood (Hawkes and Hornbostel 1996).  That 
said, in subjects fed the low-selenium diet, the lower their initial selenium status the more 
their mood tended towards depression and hostility.   
A subsequent randomized, double-blind US study that supplemented 115 HIV-
positive drug abusers with 200µg selenium daily found no difference compared to placebo 
with respect to Total Distress scores (POMS) or depression (Beck Depression Inventory) 
(Shor-Posner et al. 2003).  Higher plasma selenium levels were, however, associated with 
less anxiety (State-Trait anxiety questionnaire) and improved vigor (POMS).  However, the 
authors comment that these improvements may have been confounded by the known 
beneficial effect of selenium on immune function, resulting in fewer mycobacterial infections 
(Shor-Posner et al 2003). 
In the light of these reports, the effect of different doses of selenium on mood was 
compared to placebo as part of the UK PRECISE (PREvention of Cancer by Intervention 
with SElenium) Pilot Study.  
 
Materials and Methods 
Participants and recruitment 
The UK PRECISE pilot study was a double-blind, placebo-controlled, randomized trial 
involving volunteers from four general practices affiliated to the Medical Research Council 
General Practice Research Framework (GPRF).  Practices were deliberately chosen from 
areas of England with differing demographic characteristics: Guisborough and Linthorpe 
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(NorthEast), Bromsgrove (West Midlands) and Bungay (East Anglia).  Research nurses 
recruited similar numbers of men and women from each of three age groups: 60-64, 65-69 
and 70-74 years.  Exclusion criteria were: i) a Southwest Oncology Group performance status 
score >1 (i.e. incapable of carrying out light housework or office work); ii) active liver or 
kidney disease; iii) prior diagnosis of cancer (excluding non-melanoma skin cancer); iv) 
diagnosed HIV infection; v) on immunosuppressive therapy; vi) diminished mental capacity; 
vii) taking ≥50 µg/day of selenium supplements in the previous six months (by patient 
report).  The study had ethics committee approval and participants provided written informed 
consent to participate. 
 
Protocol 
Following a four-week placebo run-in, participants were randomly assigned to one of four 
treatment regimes: placebo, 100, 200 or 300 µg of selenium per day for two years. The 
intervention agent was high-selenium yeast, SelenoPreciseTM (Pharma Nord, Vejle, Denmark) 
or an identical placebo yeast.  Randomization was stratified by GP practice, gender and age 
group and used computer-generated permuted blocks.  Research nurses telephoned the 
independent randomization service at the Clinical Trials and Statistics Unit at the Institute of 
Cancer Research (Sutton, UK) to obtain an anonymous code for each volunteer, and then 
gave the volunteer their corresponding pre-coded tablets.  Participants and general practice 
personnel were blinded to treatment for as long as the participants remained on treatment.  
Demographic data, medical history, and other health-related information (including 
medication use) were collected at baseline.  Participants completed mood and quality-of-life 
questionnaires and provided a blood sample at both baseline and six months (when visiting 
the practices for the purpose of the PRECISE pilot).  The participants completed the 
questionnaires before blood was taken. Compliance with randomized treatment was 
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determined by pill count, with participants considered compliant if they took at least 80% of 
their allocated tablets.  Reasons for participant withdrawal were noted. 
 
Mood and Quality of Life assessment (outcome) 
Mood was assessed using the POMS-BI questionnaire (MHS, Toronto - formerly EDITS, San 
Diego; Lorr and McNair 1984).  This questionnaire, validated in the US, contains 72 
adjectives rated on a scale from "much like this" to "much unlike this" according to how the 
participants had been feeling in the past week.  For this UK study, the adjective "mad" 
(meaning "angry" in US usage) was changed to "furious" and "full of pep" to "full of energy" 
with permission from EDITS.  The adjectives are divided into six subscales, each scoring a 
maximum of 36, and can be summed to provide a "Total mood score".   Higher scores are 
associated with better mood.  An independent researcher performed scoring checks to verify 
that original scores were accurate.  
The Short Form 36 (SF-36) Health Survey (QualityMetric, Inc., Lincoln, USA) a 
standardized "quality-of-life" questionnaire, validated in Great Britain (Brazier et al. 1992; 
Garratt et al. 1993) that measures mental and physical well-being was also administered.  The 
SF-36 gives scores for nine health concepts.  Raw scores were transformed on a 0 to 100 
scale (Medical Outcomes Trust 1994) with higher scores associated with a better quality of 
life. 
 
Se measurement (outcome) 
Lithium-heparin plasma was prepared in the practices from whole blood samples, stored at -
800C and sent to Central Science Laboratory, Sand Hutton, for selenium analysis by hydride-
generation Inductively-Coupled-Plasma Mass Spectrometry.  Weighed plasma samples were 
prepared by microwave digestion (Multiwave, Perkin-Elmer, Bucks, UK) and reduced to 
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selenium (IV), before being made up to volume for analysis.  All reagents were "Analar" 
grade (or better) and the water used was Millipore-grade (18 MΩ).  Quality-control 
procedures were accredited under the UK Accreditation Scheme (UKAS).  Accuracy was 
assured by analysis of certified reference materials namely: Seronorm Serum, mean value (10 
determinations) 85.5ng/g, RSD 12.7% (certified 86ng/g); NIST 1598 Bovine Serum, mean 
value (16 determinations) 43.5ng/g, RSD 6.2% (certified 42.4±3.5ng/g).  The Limit of 
Detection was 5ng/g and the Mean Recovery 108% (12 determinations).  Plasma selenium 
measurements can be converted from ng/g to µg/L by multiplying by 1.027, the density of 
plasma. 
 
Statistical analysis  
Factors affecting total mood score after six months of supplementation (the outcome) were 
determined by ANCOVA with baseline mood as the covariate.  Randomized intervention was 
included as a four-level factor.  Participants' age group, gender and practice location (the 
stratification factors) and two a priori defined factors of smoking status (smoker/given 
up/never smoked) and antidepressant medication (yes/no) were also considered.  Factors 
significantly associated with six-month total mood score were included in the final 
multivariate model with randomized intervention.  The assumptions of normality, 
homoskedasticity, linearity and homogeneity of regression slope were tested and met for each 
ANCOVA.  All analyses were performed on the raw data, apart from the three stratification 
ANCOVAs and the one-way ANCOVAs by tablet type (active vs. placebo), smoking habit 
and antidepressant use that were carried out using square-transformed data so that the 
assumptions could be met.  Baseline comparisons between the randomized groups were made 
using t-tests and ANOVA. SF-36 data were analyzed using non-parametric methods in lieu of 
two-way ANOVA (Sokal and Rohlf 2001), with time (baseline or six months) and tablet dose 
Margaret Rayman: m.rayman@surrey.ac.uk 9
included as two main effects and an interaction.  Chi-square tests were used to analyze the 
frequency of withdrawals.  Participants who did not complete questionnaires at both baseline 
and follow-up have been excluded (complete-case analysis), however all those who did were 
included regardless of their compliance with allocated treatment.  Statistical analysis was 
performed using SPSS v11.5.1 for Windows (SPSS Inc. Chicago).   
 
 
Results 
Participants 
 
501 participants were recruited between June 2000 and July 2001 (figure 1).  
 
 
 
Compliance with treatment 
453 of the 467 participants (97%) who completed six months were compliant according to 
pill count.  Non-protocol use of over-the-counter selenium (“drop-ins”) was assessed by 
inspection of the distribution of plasma selenium concentrations in the placebo group at six 
months.  Four of the 107 participants taking placebo (3.7%) had a selenium status more than 
two standard deviations above the mean: reasonably consistent with the 2.5% expected by 
chance (being approximately normally distributed).  We have made the assumption therefore, 
that "drop-ins" were rare. Three participants reported using supplements containing 25µg of 
selenium: since this was within the 50µg daily limit imposed by our exclusion criteria, they 
have been included in the analysis. 
 
Withdrawals 
Thirty-four participants (7%) withdrew from treatment within the first six months.  There was 
no significant difference in treatment withdrawals between groups (7, 10, and 12 in the 
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placebo, 100, 200 and 300 µg groups respectively: X2=3.41, df=3, p=0.33).  Of these, 13 
withdrew because of adverse events, seven of which were abdominal/stomach problems.  
Other reasons for discontinuation appeared unrelated to treatment (figure 1). 
 
 
Selenium status  
Blood was obtained successfully from 483 participants at baseline and 429 at six months 
(with 421 having assessment at both time points).  At baseline, as expected, there were no 
significant differences in selenium concentration between the four treatment groups 
(F3,479=0.70, p=0.55).  Overall mean (SD) for all participants was 90 (19) ng/g  (i.e. 92 (20) 
µg/L).  This was higher than the 79µg/L found by the National Diet and Nutrition Survey 
(Bates et al. 2002).  After six months of supplementation, plasma selenium rose significantly 
to 145 (27), 191 (41) and 227 (53) ng/g in the 100, 200 and 300µg/d treatment groups 
respectively (F3,416=308, p<0.001): figure 2.  Selenium status did not change significantly in 
the placebo group (t=0.34, df=102, p=0.74).  
 
Mood (POMS-BI) 
The POMS-BI questionnaire was completed by 448 participants at both time points.  Mean 
scores by intervention dose are shown in table 1.  At baseline, total mood score did not differ 
significantly between the four treatment doses, the three age groups, or the four practice 
locations.  However, baseline mood was significantly higher in men than women (t=5.28, 
df=446, p<0.001), being: 170 (30) for men versus 154 (33) for women, mean difference = 16 
(95% CI: 10-22).  
Following six months of supplementation with selenium, total mood score (adjusted 
for individual variation in baseline mood) was independent of dose (F3,443=0.25, p=0.86).  
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Furthermore, none of the stratification factors (gender, age group, or practice location) 
significantly influenced adjusted six-month total mood scores (table 3).  Similarly, when all 
participants receiving the active doses (100, 200, 300µg/d) were pooled and compared to 
placebo, no effect of selenium supplementation per se was found (F1,445=0.59, p=0.44): figure 
2.  No significant effect on mood was observed from taking antidepressant medication (n=33 
participants; F1,445=0.9, p=0.35) nor according to participants' smoking habits (F2,444=1.1, 
p=0.33). 
Participants' baseline selenium status did not significantly affect the outcome of 
supplementation on mood.  When tertiles of baseline selenium status were included in the 
analysis (cut points at 79.6 and 95.4 ng/g), no significant differences in six-month total mood 
score were seen between the tertiles (F2,419=1.62, p=0.2), nor any interaction with dose 
(F6,419=0.23, p=0.97).  Initial (i.e. baseline) mood was the only significant predictor of six-
month mood in any of the models tested. 
When analyzed using the level of selenium status attained after supplementation (by 
quintiles of selenium status) rather than by intervention dose (thus taking account of possible 
"drop-ins" and non-compliers), no significant difference in mood was found between the 
quintiles (F4,403=0.49, p=0.75).  Finally, separate analyses of the six individual subscales that 
sum to create the total mood score failed to reveal any significant differences between 
treatment doses (data not reported). 
 
Quality of life (SF-36)   
The SF-36 was completed by 398 participants at both time points.  As shown previously 
(Bowling et al. 1999) the health concept scores were non-normal in their distribution.   No 
significant association was observed between any of the nine health concepts and tablet dose 
(table 2). 
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Discussion 
We set out to investigate whether we could confirm that selenium enhanced mood in a large, 
randomized, double-blind, multi-centre, placebo-controlled trial.  Our study is by far the 
largest to date to investigate the effect of selenium on mood in healthy individuals: 448 
versus 91 participants in total in the other studies.  In agreement with Hawkes and Hornbostel 
(1996) but in contrast to Benton and Cook (1991) and Finley and Penland (1998), we found 
no evidence that additional selenium enhanced mood or any of its subscales despite 
significant increases in plasma selenium. In support of our findings with the POMS-BI 
questionnaire, we found no significant effect of selenium supplementation on any of the 
subscales of the SF-36 that relate to mental state.  
Possible explanations for these different findings include: the greater age of our 
participants; our longer treatment period; better baseline selenium status and mood in our 
cohort than in some earlier work (Benton and Cook 1991) and an alternative interpretation of 
Finley and Penland's data (1998).  These possibilities are addressed below. 
Firstly the question of age: our participants were considerably older than in the studies 
of Benton and Cook (mean 36, range 14-74 years), Finley and Penland (range 18-45 years) 
and Hawkes and Hornbostel (mean 33, range 20-45 years).  While we chose the POMS-BI 
questionnaire to allow direct comparison with these previous studies, unlike the SF-36, it has 
not been validated in the elderly.  Nevertheless, equivalent coefficients of variation in scores 
for the two questionnaires suggest that responses to the POMS-BI were no more variable than 
to the SF-36.  However, changes associated with ageing could explain the different results 
observed. 
 Our participants were treated for 26 weeks compared to five and 15 weeks (Benton 
and Cook 1991, Finlay and Penland 1998) in the other studies.  Finlay and Penland (1998) 
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showed plasma selenium to plateau after six weeks of dietary supplementation where the 
major selenium source was wheat.  While wheat and selenium-yeast behave identically in 
supplementation studies in terms of their effect on plasma selenium (both having 
selenomethionine as their main selenium-containing species) (Levander et al. 1983), other 
studies suggest the process can take considerably longer: 11 weeks (Alfthan et al. 1991) and 
25 weeks (Thomson et al. 1993).  Furthermore, selenoenzyme activity can take from five to 
20 weeks to plateau depending on the tissues involved (Thomson et al. 1993).  This suggests 
that in a five-week study (Benton and Cook 1991), and perhaps to a lesser extent a 15-week 
study (Finlay and Penland 1998), selenium status and selenoenzyme activity may not have 
reached a steady state in all tissues.  By contrast, after 26 weeks, our participants' selenium 
status and selenoenzyme activity had probably stabilized.  This may explain some of the 
differences between studies, but we are unable to suggest a mechanism.   
Mean baseline selenium status in our participants (92µg/L) was higher than that found 
in free-living subjects (79µg/L) in the UK National Diet and Nutrition Survey (Bates et al. 
2002).  This is perhaps not too surprising as our participants were younger (60-74 versus 65-
74) and were healthy volunteers, a quarter of whom came from East Anglia where selenium 
status is relatively high (Caygill et al 1989).  While Benton and Cook (1991) did not measure 
selenium status, their subjects, recruited in South Wales, may have had a lower selenium 
status.  Furthermore, mean baseline mood score in Benton and Cook's subjects was also 
lower than in both this study and that of Hawkes and Hornbostel (1996).  It then increased to 
a level similar to that found at baseline and follow-up in this study and Hawkes and 
Hornbostel's work.  However, if low selenium status were the cause of low mood score, one 
might have expected to see a significant interaction between selenium status and intervention 
dose.  We found none.  Moreover, it is not clear from the results reported by Benton and 
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Cook (1991) that their analysis appropriately accounted for the crossover design of their 
study. 
Lastly, it is possible that Finley and Penland (1998) may have been observing 
regression to the mean rather than changes in mood accompanying high- or low-selenium 
diets (Macallan and Sedgwick 2000).  Their two treatment groups were not equivalent in 
mood at the beginning of the study, the low selenium group having higher baseline scores 
than the high selenium group.  This initial difference in mood (illustrated in their paper) was 
greater than the change exhibited by either group during the trial.   Furthermore, the low 
selenium diet did not significantly reduce plasma selenium levels from baseline values. 
On reflection, it is perhaps unsurprising that we saw no effect of selenium 
supplementation on mood.  Animal studies have shown that the brain is a privileged site for 
selenium retention in deficiency (Behne et al 1988; Buckman et al 1993; Whanger 2001).  
For example, Behne and colleagues (Behne and Kyriakopoulos 2001) showed that even when 
rats had been severely depleted of selenium through six generations resulting in a decrease in 
liver, skeletal muscle and blood selenium concentrations to below 1% of normal levels, the 
brain still contained 60% of the concentration found in controls.   
Mean baseline plasma selenium in our cohort was arguably in the replete range 
(Alfthan et al. 1991; Thomson et al. 1993; Duffield et al.1999) where selenoproteins may 
already be adequately supplied with selenium.  For example, the iodothyronine deiodinases, 
are adequately supplied with selenium at this plasma concentration (Beech et al 1995; 
Duffield et al 1999), so there is no risk of hypothyroidism due to selenium deficiency nor its 
associated adverse mood states of depression, lethargy and malaise (Reus 1993).  This is not 
necessarily to imply that the selenium status of our participants was optimal, since it has been 
found that selenium at “supra-nutritional” intakes may confer protection against cancer and 
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augment the immune response (Combs 2001; Kiremidjian-Schumacher et al. 1994; Rayman 
2000).  
In conclusion, we have found that selenium supplementation in a randomized, double-
blind, multi-centre, placebo-controlled trial in 501 UK elderly subjects of moderate selenium 
status did not benefit their mood or quality of life.  Though this is at odds with the findings of 
two smaller studies in other healthy individuals (Benton and Cook 1991, Finley and Penland 
1998) our robust study design, large sample size and longer supplementation period, taken 
together with the evidence that the brain is a privileged site for selenium retention, suggest 
that this is a reliable finding.  Populations of lower selenium status, worse mood, or younger 
age however, may show a different outcome.  We find no justification for increasing 
selenium intake to improve mood in the general UK elderly population. 
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 Table 1. POMS-BI subscale and total mood scores at baseline and six months by tablet dose.  
Data are means (SD) scored out of 36 for each subscale and 216 for the composite total mood 
score.  Higher scores indicate better mood.   
 
 
  
 
 
Intervention dose 
    
Mood subscale 
    
Month 
 
Placebo 
n = 112 
 
100µg 
n = 111 
 
200µg 
n = 116 
 
300µg 
n = 109 
 
Composed - Anxious 
 
0 
6 
 
27 (8)  
27 (7)  
 
27 (7)  
27 (8) 
 
28 (7)  
27 (7) 
 
27 (7)  
28 (6) 
Agreeable - Hostile 0 
6 
30 (5)  
30 (5) 
30 (6)  
30 (6) 
30 (6)  
29 (6) 
30 (5)  
29 (6) 
Elated - Depressed 0 
6 
27 (7)  
28 (7) 
27 (6)  
27 (6) 
27 (6)  
28 (6) 
27 (6)  
27 (7) 
Confident - Unsure 0 
6 
24 (7)  
24 (8) 
25 (8)  
25 (7) 
25 (6)  
25 (7) 
24 (6)  
25 (7) 
Energetic - Tired 0 
6 
25 (7)  
24 (8) 
25 (8)  
24 (8) 
25 (7)  
24 (8) 
24 (7)  
24 (7) 
Clearheaded - Confused 0 
6 
29 (6)  
29 (7) 
29 (6)  
29 (7) 
29 (6)  
29 (6) 
30 (6)  
30 (6) 
Total mood score 0 
6 
161 (34) 
163 (36) 
162 (36) 
161 (37) 
164 (32) 
162 (35) 
163 (29) 
162 (34) 
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Table 2. SF36 Health Concept scores at baseline and six months by tablet dose. Higher 
scores indicate a better quality of life.  Data are medians and interquartile ranges. P-values 
refer to the interaction between time of visit and intervention dose. 
 
 
  
 
  
Intervention dose 
 
Health concept 
 
Month 
 
Placebo 
n = 100 
 
100µg 
n = 96 
 
200µg 
n = 105 
 
300µg 
n = 97 
 
Physical Functioning 
(p = 0.97) 
 
0 
6 
 
90 (75-95) 
89 (76-95) 
 
85 (70-95) 
85 (65-95) 
 
90 (75-95) 
85 (75-95) 
 
90 (75-95) 
85 (75-95) 
Role - Physical 
(p = 0.87) 
0 
6 
94 (77-100) 
94 (75-100) 
100 (75-100) 
94 (63-100) 
94 (78-100) 
94 (75-100) 
100 (75-100) 
94 (75-100) 
Role - Emotional 
(p = 0.90) 
0 
6 
100 (92-100) 
100 (92-100) 
100 (100-100) 
100 (100-100) 
100 (100-100) 
100 (100-100) 
100 (100-100) 
100 (100-100) 
Bodily Pain 
(p = 0.98) 
0 
6 
79 (62-100) 
84 (61-100) 
74 (54-100) 
77 (51-100) 
84 (62-100) 
74 (62-100) 
84 (62-100) 
84 (62-100) 
General Health 
(p = 0.94) 
0 
6 
77 (62-87) 
77 (63-86) 
72 (62-87) 
72 (61-84) 
77 (67-87) 
77 (67-87) 
75 (62-87) 
72 (67-86) 
Vitality 
(p = 0.94) 
0 
6 
69 (59-75) 
69 (50-81) 
69 (50-81) 
75 (56-81) 
75 (60-81) 
75 (56-81) 
69 (56-75) 
69 (56-81) 
Social Functioning 
(p = 0.98) 
0 
6 
100 (88-100) 
100 (88-100) 
100 (88-100) 
100 (78-100) 
100 (100-100) 
100 (100-100) 
100 (100-100) 
100 (100-100) 
Mental health 
(p = 1.0) 
0 
6 
85 (75-90) 
85 (75-90) 
85 (70-90) 
85 (70-90) 
90 (80-95) 
90 (75-92) 
85 (75-90) 
85 (75-90) 
Health transition 
(p = 0.85) 
0 
6 
50 (50-50) 
50 (50-50) 
50 (50-50) 
50 (50-50) 
50 (50-50) 
50 (50-50) 
50 (50-50) 
50 (50-50) 
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Table 3:  ANCOVA summary output.  In each total mood score at follow-up is the dependent 
variable and baseline mood the covariate. Baseline mood is the only significant predictor of 
six month mood. Effect sizes are presented as partial eta-squared (ηp2). 
 
 
 
(i) Intervention dose 
 d.f. MS F
 
p 
 
ηp2 
 Baseline mood 
Dose (0,100, 200, 300µg/d) 
Error 
1
3
443
264603
167
659
401
0.25
<0.001 
0.859 
0.475 
0.002 
 R2 = 0.475      
 
(ii) Gender 
 d.f. MS F
 
p ηp2 
 Baseline mood 
Gender  
Error 
1
1
445
2.3x1010 
9.9x106
5.9x107
392
0.17
<0.001 
0.682 
0.468 
<0.001 
 R2 = 0.487      
 
(iii) Age group 
 d.f. MS F
 
p ηp2 
 Baseline mood 
Age group (60-64, 65-69, 70-74) 
Error 
1
2
444
2.5x1010 
1.7x107
5.9x107
419
0.30
<0.001 
0.745 
0.486 
0.001 
 R2 = 0.488      
 
(iv)  GP practice location 
 d.f. MS F
 
p ηp2 
 Baseline mood 
Practice location 
Error 
1
3
443
2.5x1010 
7.4x107
5.9x107
426
1.25
<0.001 
0.291 
0.490 
0.008 
 R2 = 0.492      
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Figure 1:  Participant flow through the study 
 
Figure 2:  Selenium status was significantly altered by supplementation.  Data are means and 
95% CIs at baseline (-) and six month follow-up (■) for the four intervention doses.  Plasma 
selenium concentration can be converted to µg/L by multiplying by 1.027, the density of 
plasma. 
 
Figure 3:  POMS-BI total mood scores at baseline and follow-up (6 months) for participants 
taking active selenium (○- - -) or placebo (▲──).  Regression lines and 95% CIs are shown 
for illustration purposes only as actual analyses were performed on square-transformed data. 
